HUE060711T2 - Makrociklusos vegyületek betegségek kezelésére - Google Patents

Makrociklusos vegyületek betegségek kezelésére

Info

Publication number
HUE060711T2
HUE060711T2 HUE18893293A HUE18893293A HUE060711T2 HU E060711 T2 HUE060711 T2 HU E060711T2 HU E18893293 A HUE18893293 A HU E18893293A HU E18893293 A HUE18893293 A HU E18893293A HU E060711 T2 HUE060711 T2 HU E060711T2
Authority
HU
Hungary
Prior art keywords
treating diseases
macrocyclic compounds
macrocyclic
compounds
diseases
Prior art date
Application number
HUE18893293A
Other languages
English (en)
Inventor
Evan W Rogers
Jingrong Jean Cui
Dayong Zhai
Han Zhang
Jane Ung
Wei Deng
Jeffrey Whitten
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Publication of HUE060711T2 publication Critical patent/HUE060711T2/hu

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HUE18893293A 2017-12-19 2018-12-18 Makrociklusos vegyületek betegségek kezelésére HUE060711T2 (hu)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762607528P 2017-12-19 2017-12-19
US201862727124P 2018-09-05 2018-09-05
US201862779283P 2018-12-13 2018-12-13

Publications (1)

Publication Number Publication Date
HUE060711T2 true HUE060711T2 (hu) 2023-04-28

Family

ID=66992951

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE18893293A HUE060711T2 (hu) 2017-12-19 2018-12-18 Makrociklusos vegyületek betegségek kezelésére

Country Status (26)

Country Link
US (3) US10745416B2 (hu)
EP (2) EP3728271B1 (hu)
JP (2) JP7194188B2 (hu)
KR (1) KR20200101358A (hu)
CN (1) CN111511746B (hu)
AU (1) AU2018392332B2 (hu)
BR (1) BR112020012319A2 (hu)
CA (1) CA3083674A1 (hu)
CL (1) CL2020001632A1 (hu)
DK (1) DK3728271T3 (hu)
EC (1) ECSP20033467A (hu)
ES (1) ES2929467T3 (hu)
HR (1) HRP20221502T1 (hu)
HU (1) HUE060711T2 (hu)
IL (1) IL275265B2 (hu)
JO (1) JOP20200152A1 (hu)
LT (1) LT3728271T (hu)
MX (1) MX2020006490A (hu)
PH (1) PH12020550901A1 (hu)
PL (1) PL3728271T3 (hu)
PT (1) PT3728271T (hu)
RS (1) RS63787B1 (hu)
SG (1) SG11202005590PA (hu)
SI (1) SI3728271T1 (hu)
TW (1) TW201930312A (hu)
WO (1) WO2019126121A1 (hu)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI787018B (zh) 2015-11-02 2022-12-11 美商纜圖藥品公司 轉染過程重排之抑制劑
KR20200089264A (ko) 2017-10-18 2020-07-24 인사이트 코포레이션 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
RS62710B1 (sr) 2017-12-19 2022-01-31 Bristol Myers Squibb Co Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti
ES2929467T3 (es) 2017-12-19 2022-11-29 Turning Point Therapeutics Inc Compuestos macrocíclicos para tratar enfermedades
FI3773589T3 (fi) 2018-04-03 2024-02-01 Blueprint Medicines Corp Ret-estäjä käytettäväksi ret-muunnoksen sisältävän syövän hoidossa
CN112703014A (zh) 2018-08-10 2021-04-23 缆图药品公司 Egfr突变型癌症的治疗
MX2021004538A (es) 2018-10-22 2021-09-10 Esker Therapeutics Inc Inhibidores de tyk2 y sus usos.
WO2020257165A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for use in treating disease
AU2020294627A1 (en) 2019-06-19 2022-02-17 Turning Point Therapeutics, Inc. Polymorphs of a macrocyclic kinase inhibitor
WO2020257189A1 (en) * 2019-06-19 2020-12-24 Turning Point Therapeutics, Inc. Macrocycles for treating disease
WO2021027503A1 (zh) * 2019-08-12 2021-02-18 罗欣药业(上海)有限公司 三环类化合物、其制备方法、中间体及应用
CN114929710B (zh) * 2019-12-03 2024-03-29 特普医药公司 用于治疗疾病的巨环
JP2023528907A (ja) 2020-06-04 2023-07-06 シンノハブ ファーマシューティカル カンパニー,リミティド 大環状構造を有する化合物及びその使用
WO2023060022A1 (en) * 2021-10-05 2023-04-13 Turning Point Therapeutics, Inc. Synthesis of macrocyclic compounds
WO2024017380A1 (zh) * 2022-07-22 2024-01-25 南京明德新药研发有限公司 含三并环的大环类化合物及其应用
WO2024040131A1 (en) * 2022-08-17 2024-02-22 Treeline Biosciences, Inc. Pyridopyrimidine kras inhibitors
JP2024120437A (ja) 2023-02-24 2024-09-05 キヤノン株式会社 撮像装置、撮像装置の制御方法、及びプログラム

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0690843B1 (en) * 1993-03-25 2000-08-30 PHARMACIA & UPJOHN COMPANY Formyl- or cyano- substituted indole derivatives having dopaminergic activity
YU49200B (sh) 1993-12-07 2004-09-03 Eli Lilly And Company Inhibitori proteinske kinaze c
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
AU2737102A (en) 2000-12-08 2002-06-18 Ortho Mcneil Pharm Inc Macroheterocylic compounds useful as kinase inhibitors
US8815872B2 (en) 2008-09-08 2014-08-26 Merck Patent Gmbh Macrocyclics pyrimidines as aurora kinase inhibitors
CN102224153B (zh) 2008-09-22 2014-04-30 阵列生物制药公司 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物
KR102037619B1 (ko) 2008-10-22 2019-10-28 어레이 바이오파마 인크. TRK 키나아제 억제제로서 치환된 피라졸로[1,5­a] 피리미딘 화합물
PE20131197A1 (es) 2008-10-31 2013-11-06 Genentech Inc Compuestos de pirazolopirimidina como inhibidores de jak y composiciones farmaceuticas que los contienen
NZ598766A (en) 2009-10-13 2013-09-27 Elanco Animal Health Ireland Macrocyclic integrase inhibitors
SA111320200B1 (ar) 2010-02-17 2014-02-16 ديبيوفارم اس ايه مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
DK2918588T3 (en) 2010-05-20 2017-08-28 Array Biopharma Inc Macrocyclic compounds as TRK kinase inhibitors
US8637516B2 (en) 2010-09-09 2014-01-28 Irm Llc Compounds and compositions as TRK inhibitors
EP2508607A1 (en) 2011-04-07 2012-10-10 Helmholtz-Zentrum für Infektionsforschung GmbH Medicament for liver regeneration and for treatment of liver failure
WO2013001310A1 (en) 2011-06-30 2013-01-03 Centro Nacional De Investigaciones Oncológicas (Cnio) Macrocyclic compounds and their use as cdk8 inhibitors
BR112014003802A2 (pt) 2011-08-19 2017-06-13 Merck Sharp & Dohme composto, composto composição farmacêutica, uso de um composto, método para fabricar um composto, e, preparação de um medicamento
DK2760867T3 (en) 2011-09-30 2016-04-11 Oncodesign Sa Macrocyclic FLT3 kinase inhibitors
DK2822953T5 (en) 2012-03-06 2017-09-11 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
MX345830B (es) 2012-03-09 2017-02-17 Lexicon Pharmaceuticals Inc Compuestos a base de pirazol[1,5-a]pirimidina, composiciones que los comprenden, y metodos para su uso.
JP6418949B2 (ja) 2012-03-09 2018-11-07 レクシコン ファーマシューティカルズ インコーポレイテッド イミダゾ[1,2−b]ピリダジン系化合物、それを含む組成物、及びそれらを使用する方法
GB201205669D0 (en) 2012-03-30 2012-05-16 Agency Science Tech & Res Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof
CN110317214B (zh) 2014-01-24 2022-11-22 特普医药公司 作为蛋白质激酶的调节剂的二芳基巨环
US10457691B2 (en) * 2014-07-21 2019-10-29 Dana-Farber Cancer Institute, Inc. Macrocyclic kinase inhibitors and uses thereof
AU2016287568B2 (en) 2015-07-02 2020-08-20 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
EP4397665A3 (en) 2015-07-06 2024-08-21 Turning Point Therapeutics, Inc. Diaryl macrocycle polymorph
AU2016296878B2 (en) 2015-07-21 2020-12-17 Turning Point Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof
CN110407856B (zh) * 2016-03-03 2021-04-13 深圳市塔吉瑞生物医药有限公司 一种大环化合物及包含该化合物的组合物
CN106008531B (zh) * 2016-05-30 2019-01-11 上海交通大学 多环稠合大环内酰胺类化合物的抗胰腺癌用途
RU2019105587A (ru) 2016-07-28 2020-08-28 Тёрнинг Поинт Терапьютикс, Инк. Макроциклические ингибиторы киназ
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
EP3658148B1 (en) 2017-07-28 2024-07-10 Turning Point Therapeutics, Inc. Macrocyclic compounds and uses thereof
KR20200089264A (ko) 2017-10-18 2020-07-24 인사이트 코포레이션 Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체
RS62710B1 (sr) 2017-12-19 2022-01-31 Bristol Myers Squibb Co Triazol n-vezane karbamoil cikloheksil kiseline kao lpa antagonisti
ES2929467T3 (es) 2017-12-19 2022-11-29 Turning Point Therapeutics Inc Compuestos macrocíclicos para tratar enfermedades
EP3728270A4 (en) * 2017-12-19 2021-06-23 Turning Point Therapeutics, Inc. MACROCYCLIC KINASE INHIBITORS AND THEIR USES
GB201721235D0 (en) 2017-12-19 2018-01-31 Syngenta Participations Ag Polymorphs
WO2019120267A1 (zh) 2017-12-22 2019-06-27 成都先导药物开发股份有限公司 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂
KR102621272B1 (ko) 2018-04-18 2024-01-05 히트젠 주식회사 거대고리 키나아제 억제제

Also Published As

Publication number Publication date
US10745416B2 (en) 2020-08-18
JOP20200152A1 (ar) 2022-10-30
RS63787B1 (sr) 2022-12-30
SI3728271T1 (sl) 2023-01-31
IL275265B2 (en) 2023-07-01
ECSP20033467A (es) 2020-09-30
US20200190110A1 (en) 2020-06-18
US11286265B2 (en) 2022-03-29
CA3083674A1 (en) 2019-06-27
CN111511746A (zh) 2020-08-07
JP7194188B2 (ja) 2022-12-21
MX2020006490A (es) 2020-08-17
SG11202005590PA (en) 2020-07-29
PH12020550901A1 (en) 2021-05-17
DK3728271T3 (da) 2022-12-19
TW201930312A (zh) 2019-08-01
EP4151641A1 (en) 2023-03-22
IL275265A (en) 2020-07-30
JP2023027237A (ja) 2023-03-01
IL275265B1 (en) 2023-03-01
WO2019126121A1 (en) 2019-06-27
PT3728271T (pt) 2022-10-06
BR112020012319A2 (pt) 2020-11-24
US20220306652A1 (en) 2022-09-29
KR20200101358A (ko) 2020-08-27
LT3728271T (lt) 2022-12-12
PL3728271T3 (pl) 2023-01-23
US20200392160A1 (en) 2020-12-17
CN111511746B (zh) 2024-01-09
EP3728271A1 (en) 2020-10-28
HRP20221502T1 (hr) 2023-03-31
AU2018392332A1 (en) 2020-06-11
ES2929467T3 (es) 2022-11-29
JP2021506850A (ja) 2021-02-22
EP3728271B1 (en) 2022-09-28
CL2020001632A1 (es) 2020-11-20
EP3728271A4 (en) 2021-06-23
AU2018392332B2 (en) 2023-08-03

Similar Documents

Publication Publication Date Title
SI3728271T1 (sl) Makrociklične spojine za zdravljenje bolezni
HK1247202A1 (zh) 用於治療癌症的化合物
SG11201705093UA (en) Composition for treating il-6-related diseases
IL249229B (en) Compounds for the treatment of brain cancer
GB201709402D0 (en) Compounds for treating t-pll
IL251790A0 (en) Compounds include thiazole for the treatment of culture diseases
IL259297A (en) Heterocyclic compounds for the treatment of disease
ZA201906047B (en) Compounds for treating tuberculosis
GB201716942D0 (en) Therapeutic compounds
ZA201901578B (en) Combinations including abx196 for the treatment of cancer
EP3383852A4 (en) COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES
PL3630754T3 (pl) Związki izoindolinoacetylenowe do leczenia nowotworu
EP3261635A4 (en) Compounds for treating ocular diseases
GB201420348D0 (en) Compounds for treating neurodegenerative diseases
ZA201805215B (en) Preparation for nasal-nasopharyngeal treatment
GB201715210D0 (en) Macrocyclic compounds
ZA201704589B (en) Compounds for the treatment of cancer
GB201712395D0 (en) Therapeutic compounds
GB201712392D0 (en) Therapeutic compounds
GB201712388D0 (en) Therapeutic compounds
GB201712393D0 (en) Therapeutic compounds
GB201712394D0 (en) Therapeutic compounds
GB201712390D0 (en) Therapeutic compounds
GB201704125D0 (en) Macrocyclic Compounds
GB201704121D0 (en) Macrocyclic compounds